Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Income (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Non Operating Income data on record, last reported at $23.4 million in Q4 2025.

  • For Q4 2025, Non Operating Income rose 12001.52% year-over-year to $23.4 million; the TTM value through Dec 2025 reached -$132000.0, changed N/A, while the annual FY2025 figure was -$132000.0, N/A changed from the prior year.
  • Non Operating Income reached $23.4 million in Q4 2025 per LCTX's latest filing, up from -$26.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $23.4 million in Q4 2025 and bottomed at -$26.0 million in Q3 2025.
  • Average Non Operating Income over 5 years is -$274611.1, with a median of $56000.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: crashed 362.68% in 2022, then soared 12001.52% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $393000.0 in 2021, then crashed by 1016.79% to -$3.6 million in 2022, then skyrocketed by 149.82% to $1.8 million in 2023, then plummeted by 110.97% to -$197000.0 in 2024, then skyrocketed by 12001.52% to $23.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $23.4 million in Q4 2025, -$26.0 million in Q3 2025, and $26000.0 in Q2 2025.